Objectives: Yellow fever-associated viscerotropic disease (YEL-AVD) is a rare but serious complication arising from administration of live-attenuated yellow fever vaccine to individuals with risk factors such as thymectomy. At present there is no evidence-based treatment, and case fatality rates are high. Sofosbuvir, an NS5B nucleotide inhibitor, has activity against yellow fever virus in vitro and in vivo.
View Article and Find Full Text PDFObjectives: Evaluating the outcomes of enhanced case management (ECM) for patients with tuberculosis (TB) in the North Central London TB Service (NCLTBS).
Design: Retrospective cohort study.
Setting: The NCLTBS provides care for persons diagnosed with TB across north and central London.
Background: Unintended extubations remain a common complication across neonatal intensive care units, with very low birthweight infants being the most vulnerable of them all. Ongoing efforts across different institutions exist with the goal of reducing the rate of unintended extubations to keep a median rate of <2 events per 100 ventilator days as defined by the Vermont Oxford Network. Our objective was to reduce unintended extubations in the very low birthweight infant in a large delivery hospital to ≤2/100 ventilator days.
View Article and Find Full Text PDFThe full electrification of transportation will require batteries with both 3-5× higher energy densities and a lower cost than what is available in the market today. Energy densities of >1000 W h kg will enable electrification of air transport and are among the very few technologies capable of achieving this energy density. Li-O or Li-air are theoretically able to achieve this energy density and are also capable of reducing the cost of batteries by replacing expensive supply chain constrained cathode materials with "free" air.
View Article and Find Full Text PDF